BR112022008216A2 - Compostos de d-anfetamina, composições e processos de fabricação e uso dos mesmos - Google Patents

Compostos de d-anfetamina, composições e processos de fabricação e uso dos mesmos

Info

Publication number
BR112022008216A2
BR112022008216A2 BR112022008216A BR112022008216A BR112022008216A2 BR 112022008216 A2 BR112022008216 A2 BR 112022008216A2 BR 112022008216 A BR112022008216 A BR 112022008216A BR 112022008216 A BR112022008216 A BR 112022008216A BR 112022008216 A2 BR112022008216 A2 BR 112022008216A2
Authority
BR
Brazil
Prior art keywords
compositions
manufacturing processes
amphetamine compounds
amphetamine
compounds
Prior art date
Application number
BR112022008216A
Other languages
English (en)
Inventor
Guenther Sven
Chi Guochen
Mickle Travis
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of BR112022008216A2 publication Critical patent/BR112022008216A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

São divulgados compostos de d-anfetamina e composições compreendendo pelo menos um ácido orgânico covalentemente ligado à d-anfetamina, um sal dos mesmos, um derivado dos mesmos ou uma combinação dos mesmos. Métodos de fabricação e uso dos mesmos também são divulgados.
BR112022008216A 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos de fabricação e uso dos mesmos BR112022008216A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752324P 2018-10-29 2018-10-29
US201962800494P 2019-02-02 2019-02-02
US16/667,804 US11136295B2 (en) 2018-10-29 2019-10-29 D-amphetamine compounds, compositions, and processes for making and using the same
PCT/US2020/019140 WO2021086426A1 (en) 2018-10-29 2020-02-21 D-amphetamine compounds, compositions, and processes for making and using the same

Publications (1)

Publication Number Publication Date
BR112022008216A2 true BR112022008216A2 (pt) 2022-07-12

Family

ID=70328134

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022008208A BR112022008208A2 (pt) 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos
BR112022008216A BR112022008216A2 (pt) 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos de fabricação e uso dos mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022008208A BR112022008208A2 (pt) 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos

Country Status (12)

Country Link
US (4) US11174229B2 (pt)
EP (2) EP4051269A4 (pt)
JP (3) JP2023501967A (pt)
KR (2) KR20220088727A (pt)
CN (2) CN114746091A (pt)
AU (2) AU2020376735A1 (pt)
BR (2) BR112022008208A2 (pt)
CA (2) CA3158404A1 (pt)
IL (2) IL292497A (pt)
MX (2) MX2022005013A (pt)
WO (2) WO2021086426A1 (pt)
ZA (2) ZA202204678B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02504509A (ja) * 1987-08-07 1990-12-20 ジ・アップジョン・カンパニー 非ペプチド結合を有するレニン抑制ペプチド
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
AU2004251647B2 (en) 2003-05-29 2010-01-14 Takeda Pharmaceutical Company Limited Abuse resistant amphetamine compounds
WO2007022535A2 (en) 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
AU2010252740A1 (en) 2009-05-26 2012-01-12 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
MX362571B (es) 2011-07-28 2019-01-25 Kempharm Inc Star Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
BR102012004888A2 (pt) 2012-03-05 2013-10-22 Phartrials Pesquisas Farmaceuticas Ltda Associação de um derivado de sulfamato monossubstituído do monossacarídeo natural d-frutose (topiramato) com um anti-depressivo da classe das fenilcetonas (bupropiona) para tratamento de obesidade e das síndromes plurimetabólicas
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
AU2013326850B2 (en) * 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
CN104812388A (zh) * 2012-10-05 2015-07-29 斯菲拉制药私人有限公司 新型化合物、其合成及其用途
ITUA20161706A1 (it) * 2016-03-15 2017-09-15 Cyanagen S R L Nuovi coloranti cumarinici e relativi coniugati
WO2018107132A1 (en) * 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
WO2018191219A1 (en) 2017-04-11 2018-10-18 Thottathil John K Novel alpha-hydroxy carboxylic acid and derivatives and other gras- based amide and imide prodrugs of amphetamine compounds and uses thereof
WO2020070557A1 (en) * 2018-10-02 2020-04-09 Q Biomed Inc. Modified therapeutic agent analogs of mefenamic acid
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Also Published As

Publication number Publication date
CA3158405A1 (en) 2021-05-06
US12091386B2 (en) 2024-09-17
IL292497A (en) 2022-06-01
US20200129497A1 (en) 2020-04-30
US11136295B2 (en) 2021-10-05
MX2022005012A (es) 2022-08-08
US20220064116A1 (en) 2022-03-03
CA3158404A1 (en) 2021-05-06
WO2021086426A1 (en) 2021-05-06
MX2022005013A (es) 2022-08-10
KR20220091508A (ko) 2022-06-30
JP2023501967A (ja) 2023-01-20
ZA202204747B (en) 2023-05-31
US11174229B2 (en) 2021-11-16
AU2020376735A1 (en) 2022-05-12
WO2021086427A1 (en) 2021-05-06
IL292496A (en) 2022-06-01
JP2024091930A (ja) 2024-07-05
EP4051269A4 (en) 2023-12-27
EP4051268A1 (en) 2022-09-07
JP2023501968A (ja) 2023-01-20
AU2020372736A1 (en) 2022-05-12
BR112022008208A2 (pt) 2022-07-12
ZA202204678B (en) 2023-01-25
US20200131130A1 (en) 2020-04-30
CN114746091A (zh) 2022-07-12
KR20220088727A (ko) 2022-06-28
EP4051269A1 (en) 2022-09-07
EP4051268A4 (en) 2024-01-17
US20240199551A1 (en) 2024-06-20
CN114746092A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2021000387A1 (es) Compuestos de anillo fusionado
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
DOP2020000023A (es) Nuevos derivados de quinolina
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
UY37480A (es) Nuevos derivados de quinolina
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
BR112015032689A2 (pt) composto heterocíclico fundido e uso em controle de pragas do mesmo
CY1123349T1 (el) Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
EA201990455A1 (ru) КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
CO2020013876A2 (es) Nuevos derivados de quinolina
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
UY37519A (es) Fenilamidinas y su uso como fungicidas
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112021024810A2 (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas